Assessment of Frailty in Elderly Patients With Advanced Cancers
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Percentage patients consenting for assessments out of number approached
研究概览
简要总结
This study is looking at the feasibility of performing frailty assessments on elderly patients with advanced cancers
详细描述
This study is primarily looking to see if it is feasible to assess frailty in patients age 70 years and above with advanced cancers. it is also evaluating whether there may be any correlation between these assessments and toxicity and treatment and outcome.
The assessments include: Frailty score, nutritional assessment, comorbidity score and quality of life. In addition sarcopenia will be assessed using timed walk, grip strength and muscle mass measurement from imaging performed as part of routine clinical care.
The assessments will be performed at baseline, week 12 and week 24.
There is the option for patients to also donate blood samples for research purposes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological diagnosis of advanced carcinoma - not suitable for curative treatment
- •Age 70 years or over
- •seen by an oncologist for consideration of palliative systemic medical therapy and decision regarding management already made
- •WHO Performance Status 0-2
- •Written informed consent
排除标准
- •Hepatocellular cancer
- •Prostate cancer
- •Breast cancer
结局指标
主要结局
Percentage patients consenting for assessments out of number approached
时间窗: Baseline
Number of patients consenting for the study as a percentage of number of patients approached about the study.
Time taken to complete assessments
时间窗: Baseline, week 12 and week 24
Length of time participants take to complete study assessments
次要结局
- Sarcopenia as a predictor of outcome(baseline, week 12 and week 24)
- Frailty as a predictor of grade 3/4 toxicity(baseline)
- Quality of life EORTC QCQ 30(baseline, week 12 and week 24)
- Biomarker assessment of frailty and associated factors which may include genetic analysis(baseline, week 12 and week 24)